SOURCE: Therapeutic Solutions International, Inc.

Therapeutic Solutions International, Inc.

January 29, 2013 09:15 ET

Therapeutic Solutions International, Inc. Announces New Distribution Agreement With Dentorient Fuss Ltd., of Tel Aviv, Israel

OCEANSIDE, CA--(Marketwire - Jan 29, 2013) - Therapeutic Solutions International, Inc. (OTCQB: TSOI) announced today the signing of a distribution agreement with Dentorient Fuss Ltd., a dental supply company headquartered in Tel Aviv, Israel.

"We are very pleased that our AMPSA products will be represented by a strong Israeli distributor, as we continue to expand our global reach," stated Tim Dixon, CEO of Therapeutic Solutions International, Inc.

Yolanda Ionescu, Import Coordinator for Dentorient Fuss Ltd., stated, "We are most pleased to enter into this distribution agreement with TSI for their Migran-X® products in Israel and look forward to bringing these products to market, because of how much these products can help patients."

About Dentorient Fuss Ltd.

Dentorient is one of the longest-established companies in Israel engaged in the import, marketing and distribution of dental materials. Their website is www.dentorientfuss.co.il.

About Therapeutic Solutions International, Inc.

Therapeutic Solutions International is a global manufacturer of the chairside anterior midpoint stop appliance (AMPSA) devices marketed internationally under the trade names Migran-X® and AMPSA CS®, which have helped countless patients prevent debilitating migraine and tension headache pain, bruxism, clenching, grinding, and TMJ disorders. The Migran-X® and AMPSA CS® devices are the most effective non-drug US FDA cleared dental method of migraine prevention on the market today. Dentists fit the AMPSA devices on patients for the treatment of medically diagnosed migraine pain, as well as migraine associated tension-type headaches, in order to reduce their migraine signs and symptoms through the reduction of trigeminally innervated muscular activity, and to prevent bruxism and TMJ syndrome through the reduction of trigeminally innervated muscular activity. In clinical trials reviewed by the US FDA, 82% of medically diagnosed migraine sufferers using the Migran-X device averaged a 77% average reduction of migraine events in the first eight weeks of use. Successful outcomes are produced by reducing head, neck and jaw muscle contraction intensity by nearly 70%. Therapeutic Solutions International also licenses laboratories to manufacture and sell semi-custom AMPSA devices internationally. The Company is also a provider of continuing education programs in the United States focused on AMPSA devices. The Company does not sell AMPSA products in the United States. The Company's corporate website is www.therapeuticsolutionsint.com. Non-US dentists and physicians can order our AMPSA products at www.ordertsoi.com.

Safe Harbor Statement
This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although we believe that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, we can give no assurance that such expectations and assumptions will prove to have been correct. Forward-looking statements are generally identifiable by the use of words like "may," "will," "should," "could," "expect," "anticipate," "estimate," "believe," "intend," or "project" or the negative of these words or other variations on these words or comparable terminology. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous factors and uncertainties, including but not limited to the need for further financing, our exit from the US market for AMPSA products in 2013, the need to procure additional international distributors, direct competition beginning in 2013, reliance on key personnel, possible introduction of new product lines, and other specific risks set forth in our SEC filings. To the extent that statements in this press release are not strictly historical, including statements as to revenue projections, business strategy, outlook, objectives, future milestones, plans, intentions, goals, future financial conditions, future collaboration agreements, the success of the Company's development, events conditioned on stockholder or other approval, or otherwise as to future events, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements contained in this release are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made. Readers are advised to review our filings with the Securities and Exchange Commission that can be accessed over the Internet at the SEC's website located at www.sec.gov.

Contact Information

  • For more information please contact:
    Jens Dalsgaard
    President
    Constellation Asset Advisors, Inc
    (415) 524-8500
    info@constellationaa.com